GlycoVaxyn: A new Gain for GSK’s Vaccines Business

14/02/2015 - 2 minutes

GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid €167M to purchase the remaining stake in the company.

GlycoVaxyn’s innovative biological conjugation platform originates enables the development of a new generation of vaccines. The platform produces conjugate vaccines in bacterial cells by using biotechnology, avoiding chemical conjugation. It also allows the development of innovative vaccines for a wider range of indications which cannot be produced with a traditional chemical technology.

The company, a spin off from the Swiss Federal Institute of Technology (ETH Zurich), entered into research collaboration with GSK in 2012. The Swiss firm is in Phase I clinical trials with a vaccine candidate against Escherichia coli infections and is expected to initiate a Phase I for a vaccine against Shigellosis (severe diarrhea) in the US in the first quarter 2015 with the financial support of the Wellcome Trust.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member